ALK Fusion Protein Expression Recruiting Phase 2 Trials for Brigatinib (DB12267)

IndicationStatusPhase
DBCOND0090278 (ALK Fusion Protein Expression)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03868423Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid CancersTreatment